naproxen has been researched along with Atherogenesis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kourounakis, AP; Ladopoulou, E; Matralis, AN | 1 |
| Kourounakis, AP; Matralis, AN | 1 |
| Day, CA; Jacob, RF; Mason, RP; Walter, MF | 1 |
1 review(s) available for naproxen and Atherogenesis
| Article | Year |
|---|---|
A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids.
Topics: Atherosclerosis; Cell Membrane; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Lipid Peroxidation; Lipoproteins, LDL; Naproxen; Prostaglandins I; Risk Factors; Sulfones; Thromboxanes | 2007 |
2 other study(ies) available for naproxen and Atherogenesis
| Article | Year |
|---|---|
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Oxidative Stress; Probucol; Rats | 2013 |
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atherosclerosis; Biphenyl Compounds; Carrageenan; Cholesterol, Dietary; Cyclooxygenase Inhibitors; Diet, High-Fat; Drug Design; Edema; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Hypolipidemic Agents; In Vitro Techniques; Indicators and Reagents; Lipid Peroxidation; Magnetic Resonance Spectroscopy; Male; Mice; Microsomes; Phenothiazines; Picrates; Rats | 2014 |